Jacobs Levy Equity Management
BPMC

Jacobs Levy Equity Management’s Blueprint Medicines BPMC Stock Holding History

Jacobs Levy Equity Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-570,402
Closed -$50.5M – 1042
2025
Q1 		$50.5M Sell
570,402
-78,258
-12% -$7.63M 0.2% 120
2024
Q4 		$56.6M Buy
648,660
+152,573
+31% +$14M 0.2% 120
2024
Q3 		$45.9M Buy
496,087
+306,079
+161% +$30.4M 0.18% 145
2024
Q2 		$20.5M Buy
190,008
+118,567
+166% +$11.9M 0.08% 214
2024
Q1 		$6.78M Buy
+71,441
New +$6.13M 0.03% 370
2023
Q4 		– Sell
-107,023
Closed -$5.37M – 981
2023
Q3 		$5.37M Sell
107,023
-4,508
-4% -$241K 0.03% 364
2023
Q2 		$7.05M Sell
111,531
-15,321
-12% -$833K 0.04% 329
2023
Q1 		$5.71M Buy
+126,852
New +$5.71M 0.04% 367

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management's BPMC Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 570,402 shares — an estimated $50.5M sold.

Jacobs Levy Equity Management first reported a position in BPMC in Q1 2023 and held it in 8 quarters. The position peaked at $56.6M in Q4 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Jacobs Levy Equity Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 570,402 Blueprint Medicines shares in Q2 2025, an estimated $50.5M.
  • Jacobs Levy Equity Management first reported a position in Blueprint Medicines in Q1 2023 and held it in 8 quarters.
  • Jacobs Levy Equity Management's Blueprint Medicines position peaked at $56.6M in Q4 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.